The IgE isotype has several potential advantages over IgG antibodies approved by the FDA on the market to treat various cancers such as the low serum levels of IgE (generally 100,000 fold lower than IgG) that result in less competition for FcεR occupancy, lack of inhibitory FcεR, and induces a different anti-tumor immune response compared to IgG (44, 45). Here, IGHE is linked to neoplasm.